- Home
- ALOT vs PBYI Comparison
ALOT vs PBYI Comparison
Compare ALOT & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALOT
- PBYI
- Stock Information
- Founded
- ALOT 1969
- PBYI 2010
- Country
- ALOT United States
- PBYI United States
- Employees
- ALOT N/A
- PBYI N/A
- Industry
- ALOT Computer peripheral equipment
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- ALOT Technology
- PBYI Health Care
- Exchange
- ALOT Nasdaq
- PBYI Nasdaq
- Market Cap
- ALOT 110.1M
- PBYI 126.5M
- IPO Year
- ALOT N/A
- PBYI N/A
- Fundamental
- Price
- ALOT $14.00
- PBYI $2.81
- Analyst Decision
- ALOT
- PBYI Strong Buy
- Analyst Count
- ALOT 0
- PBYI 1
- Target Price
- ALOT N/A
- PBYI $7.00
- AVG Volume (30 Days)
- ALOT 13.2K
- PBYI 230.1K
- Earning Date
- ALOT 12-04-2024
- PBYI 10-31-2024
- Dividend Yield
- ALOT N/A
- PBYI N/A
- EPS Growth
- ALOT 591.76
- PBYI N/A
- EPS
- ALOT 0.83
- PBYI 0.18
- Revenue
- ALOT $150,643,000.00
- PBYI $219,143,000.00
- Revenue This Year
- ALOT N/A
- PBYI N/A
- Revenue Next Year
- ALOT N/A
- PBYI N/A
- P/E Ratio
- ALOT $16.87
- PBYI $15.41
- Revenue Growth
- ALOT 0.29
- PBYI N/A
- 52 Week Low
- ALOT $12.05
- PBYI $2.13
- 52 Week High
- ALOT $18.83
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- ALOT 50.14
- PBYI 56.62
- Support Level
- ALOT $13.70
- PBYI $2.76
- Resistance Level
- ALOT $14.60
- PBYI $2.91
- Average True Range (ATR)
- ALOT 0.54
- PBYI 0.12
- MACD
- ALOT 0.07
- PBYI 0.03
- Stochastic Oscillator
- ALOT 53.85
- PBYI 76.92
About ALOT AstroNova Inc.
AstroNova Inc designs, develops, manufactures, and distributes a broad range of specialty printers and data acquisition and analysis systems, including both hardware and software, which incorporate technologies to acquire, store, analyze, and present data in multiple formats sold under the QuickLabel, TrojanLabel and GetLabels brand names. Its target markets for hardware and software products include aerospace, apparel, automotive, avionics, chemicals, computer peripherals, communications, distribution, food and beverage, general manufacturing, packaging, and transportation. It has two segments, Product Identification (PI) and Test & Measurement (T&M). It generates the majority of its revenue from the PI segment that includes specialty printing systems and related supplies.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.